Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia

• Ramzi Abboud,
• Ezhilarasi Chendamarai,
• Michael P. Rettig,
• Kathryn M. Trinkaus,
• Peter A. Riedell,
• Camille N. Abboud,
• Armin Ghobadi,
• Iskra Pusic,
• Keith Stockerl-Goldstein,
• Mark A. Schroeder,
• Ravi Vij,
• Peter Westervelt,
• John F. DiPersio,
• Geoffrey L. Uy

Affiliations

Ramzi Abboud

Division of Oncology, Washington University School of Medicine

Ezhilarasi Chendamarai

Division of Oncology, Washington University School of Medicine

Michael P. Rettig

Division of Oncology, Washington University School of Medicine

Kathryn M. Trinkaus

Biostatistics Shared Resource Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA

Peter A. Riedell

Division of Oncology, Washington University School of Medicine

Camille N. Abboud

Division of Oncology, Washington University School of Medicine

Armin Ghobadi

Division of Oncology, Washington University School of Medicine

Iskra Pusic

Division of Oncology, Washington University School of Medicine

Keith Stockerl-Goldstein

Division of Oncology, Washington University School of Medicine

Mark A. Schroeder

Division of Oncology, Washington University School of Medicine

Ravi Vij

Division of Oncology, Washington University School of Medicine

Peter Westervelt

Division of Oncology, Washington University School of Medicine

John F. DiPersio

Division of Oncology, Washington University School of Medicine

Geoffrey L. Uy

Division of Oncology, Washington University School of Medicine